Study to Determine The Effectiveness Of Detrusitol In Patients Diagnosed With OAB
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00143377|
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : November 18, 2008
|Condition or disease||Intervention/treatment||Phase|
|Urinary Incontinence||Drug: tolterodine SR, overactive bladder||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||600 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||A Global Phase IV, Double-Blind, Placebo-Controlled, Randomized Trial To Evaluate The Effectiveness Of Detrusitol Sr 4mg On Patient's Perception Of Bladder Condition (PPBC).|
|Study Start Date :||September 2004|
|Study Completion Date :||October 2005|
- Patient Perception of Bladder Condition at 12 weeks of treatment compared to placebo.
- Other safety and efficacy measures at 12 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143377
|Study Director:||Pfizer CT.gov Call Center||Pfizer|